Your browser doesn't support javascript.
loading
Rational design of ICD-inducing nanoparticles for cancer immunotherapy.
Zhang, Zhanzhan; Pan, Zheng; Li, Qiushi; Huang, Qingqing; Shi, Linqi; Liu, Yang.
Affiliation
  • Zhang Z; College of Chemistry, Key Laboratory of Functional Polymer Materials (Ministry of Education), Nankai University, Tianjin 300071, China.
  • Pan Z; School of Medical Imaging, Tianjin Medical University, Tianjin 300203, China.
  • Li Q; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China.
  • Huang Q; School of Medical Imaging, Tianjin Medical University, Tianjin 300203, China.
  • Shi L; State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China.
  • Liu Y; School of Medical Imaging, Tianjin Medical University, Tianjin 300203, China.
Sci Adv ; 10(6): eadk0716, 2024 Feb 09.
Article in En | MEDLINE | ID: mdl-38324678
ABSTRACT
Nanoparticle-based cancer immunotherapy has shown promising therapeutic potential in clinical settings. However, current research mainly uses nanoparticles as delivery vehicles but overlooks their potential to directly modulate immune responses. Inspired by the endogenous endoplasmic reticulum (ER) stress caused by unfolded/misfolded proteins, we present a rationally designed immunogenic cell death (ICD) inducer named NanoICD, which is a nanoparticle engineered for ER targeting and retention. By carefully controlling surface composition and properties, we have obtained NanoICD that can effectively accumulate in the ER, induce ER stress, and activate ICD-associated immune responses. In addition, NanoICD is generally applicable to various proteins and enzymes to further enhance the immunomodulatory capacity, exemplified by encapsulating catalase (CAT) to obtain NanoICD/CAT, effectively alleviated immunosuppressive tumor microenvironment and induced robust antitumor immune responses in 4T1-bearing mice. This work demonstrates engineered nanostructures' potential to autonomously regulate biological processes and provides insights into the development of advanced nanomedicines for cancer treatment.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nanoparticles / Neoplasms / Antineoplastic Agents Limits: Animals Language: En Journal: Sci Adv / Sci. Adv / Science advances Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nanoparticles / Neoplasms / Antineoplastic Agents Limits: Animals Language: En Journal: Sci Adv / Sci. Adv / Science advances Year: 2024 Document type: Article